Introduction {#section1-2151459319885283}
============

In the past couple of years, the number of total hip arthroplasty (THA) has exponentially grown and is expected to continue to rise due to increasing life expectancy.^[@bibr1-2151459319885283],[@bibr2-2151459319885283]^ As a direct result, the number of patients at risk for periprosthetic fractures (PPFs) of the femur has increased. This research focuses on traumatic PPF, which is accountable for 14% of the indication of hip revision surgery.^[@bibr1-2151459319885283],[@bibr3-2151459319885283]^ Periprosthetic fractures are most often classified using the Vancouver classification in which type A are fractures of either the greater (type Ag) or the lesser (type Al) trochanter. Vancouver type B fractures are around the stem and are divided in type B1 with a fixed prosthesis, B2 with a loose prosthesis, and B3 with a loose prosthesis with severe bone loss. Vancouver type C fractures are fractures well below the tip of the stem. This classification provides patient selection for the best treatment option, and several treatment algorithms using the Vancouver classification have been developed over the years.^[@bibr4-2151459319885283]^ However, it can be extremely difficult to differentiate between the types. Lindahl et al showed that 47.3% of the preoperative classifications based on X-ray were not corresponding with the preoperative findings.^[@bibr3-2151459319885283],[@bibr4-2151459319885283]^ Since open reposition and internal fixation (ORIF) often fails in cases with a loose femoral component, implant revision surgery has been recommended in every case of possible stem loosening. However, revision surgery is a highly invasive surgery with potential very high risks for the patient's well-being.^[@bibr5-2151459319885283],[@bibr6-2151459319885283]^ Minimally invasive technique (MIT), surgical interventions involving the least possible physical trauma to the patient through a tiny incision, was defined by Oxford University Press.^[@bibr7-2151459319885283]^ The goal of MIT is to decrease surgical time, improve recovery duration, and plays a major role in treatment of geriatric patients.^[@bibr8-2151459319885283],[@bibr9-2151459319885283]^

The population affected by PPFs is relatively old and frail with an average age of 75 years.^[@bibr5-2151459319885283],[@bibr6-2151459319885283]^Several studies show that frail patients have worse clinical outcome than nonfrail patients in several operative treatments.^[@bibr10-2151459319885283][@bibr11-2151459319885283]-[@bibr12-2151459319885283]^ However, these studies did not account for different surgical techniques. We performed a retrospective study to analyze the differences in outcome between different treatments of Vancouver type B and type C PPFs. The goal of our study is to evaluate whether implant revision surgery for a PPF has a higher complication rate than ORIF and MITs, like retrograde nailing. Furthermore, do frail patients actually benefit from less invasive procedures?

Materials and Methods {#section2-2151459319885283}
=====================

Population {#section3-2151459319885283}
----------

All electronic patient files from patients with an PPF between January 2009 and January 2014 were collected from the Isala Hospital, situated in the Netherlands, a regional trauma center and training hospital. Patients with a Vancouver type A fracture, intraoperative fractures, osteogenesis imperfecta, and atraumatic PPFs were excluded ([Figure 1](#fig1-2151459319885283){ref-type="fig"}).

![Flowchart.](10.1177_2151459319885283-fig1){#fig1-2151459319885283}

Assessment of Frailty {#section4-2151459319885283}
---------------------

Frailty of the patient was calculated using the complex fracture frailty index (CFFI). This is a questionnaire designed by the researchers to preoperatively determine the vulnerability of patients.

This tool was designed to cover all determinants of frailty based on the current literature.^[@bibr10-2151459319885283],[@bibr12-2151459319885283]^ The CFFI contains 52 questionnaires about demographics, comorbidities, physical abilities, cognitive function, social factors, and laboratory parameters. A summarized overview of the items can be found in [Table 1](#table1-2151459319885283){ref-type="table"}.

###### 

Overview of the CFFI Items.

![](10.1177_2151459319885283-table1)

  ---------------------------- ------------------------- ------------------------ ---------------------
  Age                          Musculoskeletal Disease   Cognitive Disease        Cooking
  Hospital admission           Neurological disease      Oriental problems        Eating
  Body mass index              Endocrinal disease        Walking                  Shower
  Weight loss                  Psychiatric disease       Mobility at home         Money management
  Medication                   Malignancy                Tools used for walking   Live independently
  Help with medication         Other diseases            Ability to walk stairs   Live alone
  Trauma last 6 months         Pain                      Transfers                Help with household
  Cardiac failure              Sight problem             Playing sports           Daily schedule
  Vascular disease             Hearing problem           Ability to carry 5 kg    Limitations
  Hypertension                 Speech problem            Shopping                 Gloomy
  Pulmonary disease            C-reactive protein        Kneel down               Tired
  Gastric intestinal disease   Albumin                   Household (light)        Anxious
  Urogenital disease           Hemoglobin                Household (heavy)        Sleeping problems
  ---------------------------- ------------------------- ------------------------ ---------------------

Abbreviation: CFFI, complex fracture frailty index.

All of the items are scored as "0," "1/2", or "1," with 1 being the least favorable outcome. Questions like "Do you have problems with sight?" have the answers: not at all, a little, or a lot. These outcomes are added and divided by the number of items scored, resulting in an outcome between 0 and 1, with 1 being the theoretical complete frail patient. We classified patients with a score of 0.26 and higher as frail. The reason for using this specific frailty score is because it is suitable for retrospective research, and it includes many different determinants of frailty compared to the Groningen Frailty Indicator (GFI). The CFFI was validated by comparing this frailty indicator to the widely used GFI.^[@bibr13-2151459319885283]^ The power of this validation was 31 patients. The participants were asked to complete the GFI as well as the CFFI. In this group, 51.6% (n = 16) of the patients were frail according to the GFI. In 90.3% (N = 29) patients, the outcome of the GFI was in line with the bivariate outcome of the CFFI. A Spearman correlation coefficient test showed a correlation of 0.786, which proved the CFFI was a good alternative to the GFI.

The items of the CFFI for the PPF study were extracted partially from the electronic patient file, and the other items were integrated in a questionnaire with 20 items. After approval of the Medical Ethical Board, this questions were asked per phone, e-mail, or letter to the patients or their relatives.

Patient Groups {#section5-2151459319885283}
--------------

Patients were divided into 4 categories according to the CFFI: not frail (0-0.1), minor frail (0.1-0.25), major frail (0.26-0.4), and severe frail (0.41-1). In the statistical analysis, category 1 (not frail) was excluded since there was only 1 patient in this category. For other analysis, the patients were divided into groups based on the type of surgical treatment: revision of the THA, MIT, or ORIF. When a revision was combined with ORIF, the patient was allocated to the revision group.

Mortality and the number of complications were compared among the subgroups based on frailty score and type of treatment. Complications are divided into minor and major complications. Minor complications are systemic or local complications (implant-related infection, urinary tract infection, pneumonia, need of blood transfusion), which required longer hospital stay or medical treatment. Major complications are mortality within 1 year, reoperation within 1 year (like refractures or implant-related infection not controlled by antibiotics alone), immobility after 1 year, and major systemic complications, which required complex medical intervention. For statistical analysis, independent sample *t* tests, χ^2^ tests, and Mann-Whitney *U* tests were used (SPSS version 20.0) were used. A *P* \< .05 was considered significant.

Results {#section6-2151459319885283}
=======

Baseline Characteristics, Minor and Major Complications, and Overall Mortality {#section7-2151459319885283}
------------------------------------------------------------------------------

Our group of 63 patients with an PPF had a 1-year mortality of 21.7%. At the moment of data analysis, 33.3% of the patients had died with an average follow-up of 30.4 months ([Figure 2](#fig2-2151459319885283){ref-type="fig"}). Of the 63 patients with an PPF, we were able to retrieve information necessary for the CFFI of 45 patients. These patients (35 females, 77.8%) had a mean age of 78.6 ± 11.2 years. In 9 patients (20.0% of total), the PPF occurred after previous revision surgery. More baseline characteristics of these 45 patients can be found in [Table 2](#table2-2151459319885283){ref-type="table"}. Minor and major complications per group of frailty category are presented in [Table 3](#table3-2151459319885283){ref-type="table"} and surgery-specific complications can be found in [Table 4](#table4-2151459319885283){ref-type="table"}.

![Survival curve.](10.1177_2151459319885283-fig2){#fig2-2151459319885283}

###### 

Baseline Characteristics Based on Frailty.

![](10.1177_2151459319885283-table2)

  Characteristic                  Total            Category 2    Category 3      Category 4
  ------------------------------- ---------------- ------------- --------------- ----------------
  Number, n (%)                   45               15 (33.3)     13 (28.9)       17 (37.8)
  Age, years^a^                   78.6 ± 11.2      71.3 ± 9.2    79.8 ± 11.0     84.6 ± 9.5
  Female, n (%)                   35 (77.8)        10 (71.4)     10 (76.9)       15 (88.2)
  BMI^a^                          25.3 ± 3.5^c^    27.1 ± 3.1    24.3 ± 3.8^c^   24.2 ± 3.3^c^
  Left, n (%)                     24 (53.3)        11 (78.6)     5 (38.5)        8 (47.1)
  Follow-up, months^b^            30 (0-80)        39 (12-73)    31 (6-80)       24 (0-62)
  Vancouver B, n (%)              25 (55.6)                      7 (53.8)        6 (35.3)
  Treatment, n (%)                                                               
   MIT                            4 (8.9)          0 (0)         1 (7.7)         3 (17.6)
   ORIF                           29 (64.4)        12 (80.0)     8 (61.5)        9 (52.9)
   Revision                       12 (26.7)        3 (21.4)      4 (30.8)        5 (29.4)
  Time after THP, months^b^       102 (0-282)^c^   84 (0-241)    69 (1-223)^c^   106 (4-282)^c^
  After primary THP, N (%)        36 (80.0)        13 (86.7)     10 (76.9)       13 (76.5)
  Score CFFI^a^                   0.35 ± 0.16      0.19 ± 0.05   0.33 ± 0.05     0.52 ± 0.08
  Minor complications,^a^ range   1.3 (0-4)        0.8 (0-2)     1.2 (0-4)       2 (0-4)
  Major complications,^a^ range   0.6 (0-3)        0.3 (0-1)     0.5 (0-1)       1.1 (0-3)

Abbreviations: BMI, body mass index; CFFI, complex fracture frailty index; MIT, minimally invasive technique; ORIF, open reposition and internal fixation; THP, total hip replacement.

^a^Mean ± standard deviation.

^b^Median (range).

^c^Missing data.

###### 

Minor and Major Criteria Divided Into Groups of Frailty.
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                                    Total   Category 2   Category 3   Category 4
  --------------------------------- ------- ------------ ------------ ------------
  Minor complications                                                 
   Implant-related infections (%)   11      1 (9.1)      3 (27.3)     7 (63.6)
   Urine tract infection (%)        4       0 (0)        1 (25.0)     3 (75.0)
   Pneumonia (%)                    2       0 (0)        0 (0)        2 (100.0)
   Blood transfusion (%)            34      9 (26.5)     9 (26.5)     16 (47.0)
   Additional (%)                   20      7 (35.0)     4 (20.0)     9 (45.0)
  Major complications                                                 
   Mortality \<30 days (%)          2       0 (0)        0 (0)        2 (100.0)
   Mortality \<90 days (%)          1       0 (0)        0 (0)        1 (100.0)
   Mortality \<1 year (%)           3       0 (0)        1 (33.3)     2 (66.7)
   Reoperation \<1 year (%)         8       3 (37.5)     1 (12.5)     4 (50.0)
   Immobility \>1 year (%)          10      0 (0)        1 (10.0)     9 (90.0)

###### 

Minor and Major Criteria Divided Into Groups of Operation Technique.

![](10.1177_2151459319885283-table4)

                                    Total   MIT       ORIF        Revision
  --------------------------------- ------- --------- ----------- -----------
  Minor complications                                             
   Implant-related infections (%)   11      0 (0)     5 (45.5)    6 (54.5)
   Urine tract infection (%)        4       0 (0)     1 (25.0)    3 (75.0)
   Pneumonia (%)                    2       0 (0)     1 (50.0)    1 (50.0)
   Blood transfusion (%)            34      1 (2.9)   22 (64.7)   11 (32.4)
   Additional (%)                   20      0 (0)     13 (65.0)   7 (35.0)
  Major complications                                             
   Mortality \<30 days (%)          2       0 (0)     1 (50.0)    1 (50.0)
  Mortality \<90 days (%)           1       0 (0)     1 (100.0)   0 (0)
   Mortality \<1 year (%)           3       0 (0)     1 (33.3)    2 (66.7)
   Reoperation \<1 year (%)         8       0 (0)     5 (62.5)    3 (37.5)
   Immobility \>1 year (%)          10      0 (0)     9 (90.0)    1 (10.0)

Abbreviations: MIT, minimally invasive technique; ORIF, open reposition and internal fixation.

Frailty {#section8-2151459319885283}
-------

After dividing the patients in categories according to the CFFI, we performed a survival analysis per category ([Figure 3](#fig3-2151459319885283){ref-type="fig"}). A significant difference in survival was found between category 2 and category 4 (*P* \< .05) and between category 2 and category 3 (*P* = .004) in favor of category 2.

![Survival curve of the categories of frailty.](10.1177_2151459319885283-fig3){#fig3-2151459319885283}

In frailty category 4, patients had a relative risk (RR) of 3.7 to experience a major complication compared to patients in category 2 (average 0.29 vs 1.06). This difference was found to be significant (*P* = .02; [Figure 4](#fig4-2151459319885283){ref-type="fig"}). Additionally, the difference in number of minor complications between category 2 and category 4 was significant (odds ratio \[OR\]: 2.5, *P* = .01). Differences in minor and major complications compared to category 3 were not significant.

![Relative risk of complications by category.](10.1177_2151459319885283-fig4){#fig4-2151459319885283}

Type of Treatment {#section9-2151459319885283}
-----------------

Patients were divided according to the type of treatment. Baseline characteristics are to be found in [Table 5](#table5-2151459319885283){ref-type="table"}. An important significant difference was found for the type of treatment, since revision surgery was not performed for Vancouver type C fractures, in contrast to ORIF in both Vancouver B and C type of fractures. No significant differences were found for survival and major or minor complications. A *P* value of .057 was found for the difference in minor complications between MITs and revision surgery (OR 3.0).

###### 

Baseline Characteristics Based on Treatment.
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  Characteristic                  Total            MIT             ORIF            Revision
  ------------------------------- ---------------- --------------- --------------- -------------
  Number, n (%)                   45               4 (8.9)         29 (64.4)       12 (26.7)
  Age, years^a^                   78.6 ± 11.2      76.5 ± 8.3      80.5 ± 10.6     74.8 ± 13.1
  Female, n (%)                   35 (77.8)        4 (100.0)       24 (82.8)       7 (58.3)
  BMI^a^                          25.3 ± 3.5^c^    23.3 ± 4.6^c^   25.9 ± 3.3^c^   24.7 ± 3.6
  Left, n (%)                     24 (53.3)        3 (75.0)        15 (51.7)       6 (50.0)
  Follow-up, months^b^            30 (0-80)        25 (18-61)      27 (0-80)       31 (0-63)
  Vancouver B, n (%)              25 (55.6)        1 (25.0)        12 (41.4)       12 (100.0)
  Time after THP, months^b^       102 (0-282)^c^   57 (20-96)      114 (1-282)     136 (0-223)
  After primary THP, n (%)        36 (80.0)        4 (100.0)       22 (75.9)       10 (83.3)
  Score CFFI^a^                   0.35 ± 0.16      0.45 ± 0.11     0.34 ± 0.17     0.34 ± 0.14
  Frail patients, n (%)           30 (66.7)        4 (100.0)       17 (58.6)       9 (75.0)
  Minor complications,^a^ range   1.3 (0-4)        0.3 (0-1)       1.2 (0-4)       2.1 (0-4)
  Major complications,^a^ range   0.6 (0-3)        0 (0-0)         0.8 (0-3)       0.6 (0-2)

Abbreviations: BMI, body mass index; CFFI, complex fracture frailty index; MIT, minimally invasive technique; ORIF, open reposition and internal fixation; THP, total hip replacement.

^a^Mean ± standard deviation.

^b^Median (range).

^c^Missing data.

Type of Treatment in Frail Patients {#section10-2151459319885283}
-----------------------------------

Of the 45 analyzed patients, 30 (66.7%) were considered frail on the CFFI (categories 3 and 4). A subgroup analysis was performed regarding complication rates. Overall survival between groups was not significantly different. The RR for a major complication between MIT and ORIF was significant (*P* = .021). The difference between ORIF and revision as well as between MIT and revision was not significant (*P* = .597 and *P* = .076). In analyzing the differences between the treatment groups for minor complications, all differences were found to be significant ([Figure 5](#fig5-2151459319885283){ref-type="fig"}). A *P* value of .019 was found for the RR between MIT and ORIF (RR 5.6). The RR between MIT and revision surgery (RR 11.0) leads to a *P* value of.007. Also, the RR for minor complications between ORIF and revision surgery (RR 1.9) was significant (*P* = .015).

![Relative risk of complications by treatment.](10.1177_2151459319885283-fig5){#fig5-2151459319885283}

Discussion {#section11-2151459319885283}
==========

In this retrospective study, Vancouver B and C PPFs were analyzed to evaluate if revision surgery for a PPF has a higher complication rate than ORIF and MITs. Second, this study aimed to show whether frail patients benefit from less invasive procedures.

The treatment of PPF is complex and has high complication rates reported in the literature, which is also confirmed in this study.^[@bibr3-2151459319885283],[@bibr5-2151459319885283],[@bibr6-2151459319885283]^ Optimization of treatment should be aimed to reduce complications and mortality. Several techniques are designed to provide less invasive procedures for this specific fracture. Large surgical procedures are often harmful and very unwanted in a frail patient group, although these procedures may be biomechanical superior to less invasive systems.

Therefore, another research goal was to determine whether frail patients detected by our frailty score CFFI were more prone to experience complications after more invasive surgery than less debilitated patients. The renewing fact of our study is the observed influence of frailty specifically in PPFs. This has not been clarified in previous reports that often focus on fracture patterns and surgical procedures alone. Furthermore, we considered the different levels of invasiveness of the treatment options, which in our opinion are highly important in these frail patients. The study population had similar baseline characteristics (age, sex, and previous revision surgery) compared to the larger studies available in PPFs.^[@bibr3-2151459319885283],[@bibr5-2151459319885283]^ As expected, the results show that frail patients have a lower overall survival compared to healthier individuals ([Figure 3](#fig3-2151459319885283){ref-type="fig"}). The frailty in this study was measured using the CFFI, which was created and validated by the authors of this study. This score meets an important need in assessing frailty in medical research, since it is the only retrospective frailty score available. Furthermore, the CFFI has a continuous outcome, which is much more in line with the gliding scale of frailty itself. The CFFI is a questionnaire to determine the frailty of patients. For some of the frail patients, it is not possible to complete the questions on their own. Risk of possible bias could lie in the situation where family members of other third persons have to complete the questionnaire. However, this is common in all other scoring systems.

After analysis of frail patients in our series, significant differences were found in major and minor complications, indicating that in these individuals more invasive surgery results in more complications. This emphasizes the need for less invasive procedures in this particular group.

What needs to be mentioned in this retrospective study is that the baseline characteristics showed a significant difference in fracture type. In the revision group, more patients were treated for a Vancouver type B fracture. Because of the current treatment guidelines, this could not be overcome, but nonetheless this difference might have biased our results.^[@bibr14-2151459319885283]^

This study with 60 patients is among the largest studies in PPFs available, with a clear focus on the extend of an operative procedure and frailty.^[@bibr3-2151459319885283],[@bibr5-2151459319885283]^ We were able to look at more patient-specific data in our cohort and derive the influence of frailty on complications and amount of surgery. The assessment of frailty in patients with an PPF is mandatory to select the appropriate surgical procedure. In all patients with PPF, we suggest an assessment of frailty with the CFFI questionnaire preoperatively to measure the frailty of the individual. This tool can help the surgeon to choose the best operation technique for the individual patient. A prospective study will be conducted to evaluate a preoperative plan tailor made using the CFFI in the patient group with an PPF. Quality of life after the different types of treatment will be measured as well.

Conclusion {#section12-2151459319885283}
==========

This study shows that frail patients with a PPF have significantly more minor complications after more invasive surgery. These findings emphasize the importance of assessing the frailty preoperatively and using this assessment in determining the optimal treatment strategy.
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